5337-09-7

Usage

Uses

Used in Pharmaceutical Industry:
METHYL 2-BROMO-3-NITROBENZOATE is used as an intermediate in the synthesis of anti-inflammatory drugs, specifically for the production of Balsalazide (B116300). This application is due to its ability to be chemically modified and incorporated into the structure of the final drug product, contributing to its therapeutic effects and potentially enhancing its anti-inflammatory properties.

InChI:InChI=1/C8H6BrNO4/c1-14-8(11)5-3-2-4-6(7(5)9)10(12)13/h2-4H,1H3

Upstream product

• 41085-43-2 2-bromo-3-nitrotoluene 
• 573-54-6 2-bromo-3-nitro-benzoic acid 
• 74-88-4 methyl iodide 
• 57113-91-4 methyl 3-nitroanthranilate 
• 53663-14-2 anhydro-2-hydroxymercuri-3-nitrobenzoic acid 
• 67-56-1 methanol 
• 856789-07-6 bis-(2-methoxycarbonyl-6-nitro-phenyl)-mercury 
• 570-24-1 2-Methyl-6-nitroaniline 

Downstream Products

• 857539-88-9 2-[1]naphthyl-3-nitro-benzoic acid methyl ester 
• 131514-77-7 methyl 3-nitro-2-<<2-<(phenylmethyl)amino>propyl>amino>benzoate 
• 77326-46-6 2-carbomethoxy-6-nitrobenzonitrile 
• 106896-48-4 methyl 2-bromo-3-aminobenzoate 
• 33358-47-3 2-Methoxycarbonyl-6-nitro-diphenylsulfid 
• 261351-28-4 2-(2-methoxy-3-phenyl-2,3-dihydro-benzofuran-6-ylamino)-3-nitro-benzoic acid methyl ester 
• 4518-10-9 Methyl 3-aminobenzoate 
• 443303-80-8 2-(6-methoxycarbonyl-2-nitrophenyl)-2-cyclohexen-1-one 
• 328546-65-2 9-nitro-1,2,3,4-tetrahydro-5H-1,4-benzodiazepin-5-one 
• 126234-13-7 methyl 2-[2-[(phenylmethyl)amino]propylamino]-3-nitrobenzoate monohydrochloride 

Relevant academic research and scientific papers

Organic electroluminescent device

The present invention relates to electronic devices, in particular organic electroluminescent devices, comprising compounds of the formula (1), to the corresponding compounds, and to a process for the preparation of these compounds.

NOVEL COMPOUNDS AS CHLORIDE CHANNEL BLOCKING AGENT

Disclosed is a novel compound to function as a calcium-dependent chloride channel blocking agent.

EBNA1 INHIBITORS AND THEIR METHOD OF USE

Pharmaceutical compositions of the invention comprise EBNA1 inhibitors useful for the treatment of diseases caused by EBNA1 activity such as cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus and rheumatoid arthritis. Pharmaceutical compositions of the invention also comprise EBNA1 inhibitors useful for the treatment of diseases caused by latent Epstein-Barr Virus (EBV) infection. Pharmaceutical compositions of the invention also comprise EBNA1 inhibitors useful for the treatment of diseases caused by lytic Epstein-Barr Virus (EBV) infection.

ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS

This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.

Monna, a potent and selective blocker for transmembrane protein with unknown function 16/anoctamin-1

Transmembrane protein with unknown function 16/anoctamin-1 (ANO1) is a protein widely expressed in mammalian tissues, and it has the properties of the classic calcium-activated chloride channel (CaCC). This protein has been implicated in numerous major physiological functions. However, the lack of effective and selective blockers has hindered a detailed study of the physiological functions of this channel. In this study, we have developed a potent and selective blocker for endogenous ANO1 in Xenopus laevis oocytes (xANO1) using a drug screening method we previously established (Oh et al., 2008). We have synthesized a number of anthranilic acid derivatives and have determined the correlation between biological activity and the nature and position of substituents in these derived compounds. A structure-activity relationship revealed novel chemical classes of xANO1 blockers. The derivatives contain a-NO2 group on position 5 of a naphthyl group-substituted anthranilic acid, and they fully blocked xANO1 chloride currents with an IC 5050 of 0.08 μM for xANO1. Selectivity tests revealed that other chloride channels such as bestrophin-1, chloride channel protein 2, and cystic fibrosis transmembrane conductance regulator were not appreciably blocked by 10～30 μM MONNA. The potent and selective blockers for ANO1 identified here should permit pharmacological dissection of ANO1/CaCC function and serve as potential candidates for drug therapy of related diseases such as hypertension, cystic fibrosis, bronchitis, asthma, and hyperalgesia.

SUBSTITUTED BENZENE COMPOUNDS

The present invention relates to substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.

Synthesis of cyclic selenenate/seleninate esters stabilized by ortho-nitro coordination: Their glutathione peroxidase-like activities

The syntheses of selenenate/seleninate esters and related derivatives by aromatic nucleophilic substitution (SNAr) reactions of 2-bromo-3-nitrobenzylalcohol (13) and 2-bromo-3-nitrobenzaldehyde (17) with Na2Se2/nBuSeNa are

A noveland practical synthesis of substituted 2-ethoxy benzimidazole: Candesartan cilexetil

A novel and practical synthetic route for the preparation of candesartan cilexetil from methyl 2-amino-3-nitrobenzoate is described.The key steps are the reaction of methyl 2-bromo-3-(diethoxy-methyleneamino)benzoate with (2-(1-trityl-1H-tetrazol-5-yl) biphenyl-4-yl) methanamine and the final formation of 2-ethoxy benzimidazole ring via intramolecular N-arylation.The final ring closure process could be utilized to prepare other 2-substituted benzimidazoles.The method is simple for operation and suitable for industrial production.

Substituted tricyclics

A class of novel tricyclics is disclosed together with the use of such compounds for inhibiting sPLA2mediated release of fatty acids for treatment of conditions such as septic shock.